Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.68 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.59 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.47 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.47 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506212 | 1.00 | PLA2G2C (0.71) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL10752879 | 1.00 | PLA2G2C (0.71) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL931685 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL21568785 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL28622692 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL23300849 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL25394384 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL22092476 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL2702607 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D | |
| SCHEMBL28781558 | 0.99 | PLA2G2C (0.73) | PLA2G2CLPAR1LPAR3LPAR2PLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024014511-A1 | LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR INDUCING ACQUIRED IMMUNITY IN LIVING BODY BY USING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE | 日油株式会社 | 2024-01-18 | — | — | WO | claimed |
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | claimed |
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| CN-115504945-A | Ionizable heterocyclic lipid molecule and application thereof in preparation of lipid nanoparticles | 南京吉迈生物技术有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-114344278-A | Nucleic acid delivery vectors and uses thereof | 南京吉迈生物技术有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113941011-A | Nano liposome particle containing ionizable cationic lipid and preparation method thereof | 浙江汇科泽华生物技术有限公司 | 2022-01-18 | — | — | CN | claimed |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2021-11-16 | — | — | US | claimed |
| EP-3397244-B1 | TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2021-10-06 | — | — | EP | claimed |
| US-11116818-B2 | Compositions and methods for inhibiting viral entry | Children's Medical Center Corporation Dana-Farber Cancer Institute (US) | 2021-09-14 | — | — | US | claimed |
| CN-108883068-B | Breast cancer treatment | 杏国新药股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| WO-2008089485-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | claimed |
| US-20060165773-A1 | Gene therapy of tumors using non-viral delivery system | PEREZ-SOLER ROMAN | 2006-07-27 | — | — | US | claimed |
| EP-1444991-A1 | Novel targeted compositions for diagnostic and therapeutic use | IMARX PHARMACEUTICAL CORP. (US) | 2004-08-11 | — | — | EP | claimed |
| EP-0845981-B1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-09-25 | — | — | EP | claimed |
| EP-0831932-A4 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP (US) | 2000-01-12 | — | — | EP | claimed |
| US-5935936-A | A DRUG DELIVERY FOR GENE THERAPY COMPRISING A DIAMINO-POLY-ALKYLAMINE-CARBAMOYL CHOLESTEROL AND AT LEAST ONE PHOSPHATIDES | GENZYME CORPORATION (US) | 1999-08-10 | — | — | US | claimed |
| EP-0831932-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040285-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0161519-B1 | DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-06-29 | — | — | EP | claimed |
| US-4717512-A | Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | PLA2G2C 565/4885LPAR1 2762/4885LPAR3 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.